

EQA round: APLA2/22 - Antiphospholipid Antibodies

Deadline: 30.09.2022

Key:	>>> ... marks correct (expected) result	N ... number of the results
	> ... marks conditionally correct (acceptable) result	Nrel ... relative number of the results
	± ... marks the result not evaluated	

Test

Sample	Group		N	Result	N _{rel}
(461) anti-cardiolipin screening					
A	(2) EIA (ELISA)	>>>	15	Positive	94 %
	(4) LIA (CLIA, CMIA, ECLIA, LOCI)	>>>	1	Positive	6,3 %
	Total per sample: n = 16	-----	Success: 100 %	-	
B	(2) EIA (ELISA)	>>>	15	Positive	94 %
	(4) LIA (CLIA, CMIA, ECLIA, LOCI)	>>>	1	Positive	6,3 %
	Total per sample: n = 16	-----	Success: 100 %	-	
Total success: 100 %					
(463) anti-cardiolipin IgG					
A	(2) EIA (ELISA)		1	Negative	1,6 %
		>>>	39	Positive	61 %
	(3) FIA (FEIA, TRACE)	>>>	4	Positive	6,3 %
	(4) LIA (CLIA, CMIA, ECLIA, LOCI)	>>>	19	Positive	30 %
	(99) Another measurement principle	>>>	1	Positive	1,6 %
	Total per sample: n = 64	-----	Success: 98 %	-	
B	(2) EIA (ELISA)		1	Negative	1,6 %
		>>>	39	Positive	61 %
	(3) FIA (FEIA, TRACE)	>>>	4	Positive	6,3 %
	(4) LIA (CLIA, CMIA, ECLIA, LOCI)	>>>	19	Positive	30 %
	(99) Another measurement principle	>>>	1	Positive	1,6 %
	Total per sample: n = 64	-----	Success: 98 %	-	
Total success: 98 %					
(464) anti-cardiolipin IgM					
A	(2) EIA (ELISA)	>>>	40	Negative	63 %
	(3) FIA (FEIA, TRACE)	>>>	4	Negative	6,3 %
	(4) LIA (CLIA, CMIA, ECLIA, LOCI)	>>>	19	Negative	30 %
	Total per sample: n = 63	-----	Success: 100 %	-	
B	(2) EIA (ELISA)	>>>	40	Negative	63 %
	(3) FIA (FEIA, TRACE)	>>>	4	Negative	6,3 %
	(4) LIA (CLIA, CMIA, ECLIA, LOCI)	>>>	19	Negative	30 %
	Total per sample: n = 63	-----	Success: 100 %	-	
Total success: 100 %					
(465) anti-beta2-GP 1 screening					
A	(2) EIA (ELISA)	>>>	13	Positive	93 %
	(4) LIA (CLIA, CMIA, ECLIA, LOCI)	>>>	1	Positive	7,1 %
	Total per sample: n = 14	-----	Success: 100 %	-	
B	(2) EIA (ELISA)	>>>	13	Positive	93 %
	(4) LIA (CLIA, CMIA, ECLIA, LOCI)	>>>	1	Positive	7,1 %
	Total per sample: n = 14	-----	Success: 100 %	-	
Total success: 100 %					
(467) anti-beta2-GP 1 IgG					
A	(2) EIA (ELISA)	>>>	39	Positive	65 %
	(3) FIA (FEIA, TRACE)	>>>	2	Positive	3,3 %
	(4) LIA (CLIA, CMIA, ECLIA, LOCI)	>>>	19	Positive	32 %
	Total per sample: n = 60	-----	Success: 100 %	-	
B	(2) EIA (ELISA)		1	Negative	1,7 %
		>>>	38	Positive	63 %
	(3) FIA (FEIA, TRACE)	>>>	2	Positive	3,3 %
	(4) LIA (CLIA, CMIA, ECLIA, LOCI)	>>>	19	Positive	32 %
	Total per sample: n = 60	-----	Success: 98 %	-	
Total success: 98 %					
(468) anti-beta2-GP 1 IgM					
A	(2) EIA (ELISA)	>>>	38	Negative	64 %
	(3) FIA (FEIA, TRACE)	>>>	2	Negative	3,4 %
	(4) LIA (CLIA, CMIA, ECLIA, LOCI)	>>>	18	Negative	31 %
	(99) Another measurement principle	>>>	1	Negative	1,7 %
	Total per sample: n = 59	-----	Success: 100 %	-	
B	(2) EIA (ELISA)	>>>	38	Negative	64 %
	(3) FIA (FEIA, TRACE)	>>>	2	Negative	3,4 %
	(4) LIA (CLIA, CMIA, ECLIA, LOCI)	>>>	18	Negative	31 %
	(99) Another measurement principle	>>>	1	Negative	1,7 %
	Total per sample: n = 59	-----	Success: 100 %	-	
Total success: 100 %					

